GSA Capital Partners LLP Sells 109,045 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

GSA Capital Partners LLP lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 75.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,313 shares of the biotechnology company's stock after selling 109,045 shares during the quarter. GSA Capital Partners LLP's holdings in ADMA Biologics were worth $706,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter worth $30,000. Quest Partners LLC acquired a new position in ADMA Biologics during the second quarter worth $29,000. EntryPoint Capital LLC acquired a new position in ADMA Biologics during the first quarter worth $31,000. USA Financial Formulas increased its holdings in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ADMA shares. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Stock Performance

Shares of ADMA stock traded up $0.50 on Monday, hitting $19.54. The company's stock had a trading volume of 2,713,004 shares, compared to its average volume of 3,662,165. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock's 50 day moving average is $18.54 and its 200-day moving average is $14.45. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a market capitalization of $4.62 billion, a PE ratio of 68.18 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period in the prior year, the company posted $0.01 earnings per share. Equities research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This represents a 10.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. Corporate insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.